Five Prime Therapeutics Inc (FPRX) Return on Equity ROE from the fourth quarter 2020 to fourth quarter 2019 and annually, average high and low, overall ranking from Dec 31 2020 to Dec 31 2019 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Five Prime Therapeutics Inc   (NASDAQ: FPRX)

Five Prime Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Five Prime Therapeutics Inc in the fourth quarter 2020?
Five Prime Therapeutics Inc recorded a cumulative net loss of $-84 million during 12 months ending in the fourth quarter 2020, resulting in a negative return on equity (ROE) of -54.86%.

Within the Major Pharmaceutical Preparations industry 215 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2020 from 0 to 3958.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter
Y / Y Equity Change 76.18 % -46.63 % -41.95 % -42.58 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -84 -95 -104 -122 -137
Return On Equity (TTM) -54.86 % -75.84 % -71.64 % -72.79 % -71.29 %
FPRX's Total Ranking # 3958 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 265 95 120 135 150
Seq. Equity Change 178.38 % -20.6 % -10.85 % -10.59 % -15.67 %
Seq. Net Income Change - - - - -

Back to FPRX Management Effectiveness >> FPRX's 5 Years Annual ROE >> Compare FPRX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 216
Sector # 505
Overall # 3958

Return On Equity Statistics
High Average Low
116.18 %
-77.31 %
-884.89 %
(Dec 31 2015)   (Mar 31 2014)





FPRX Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016
Total Equity in Millions 265 150 265 265 392
Y / Y Equity Change 76.18 % -43.25 % -0.02 % -32.27 % -9.61 %
Net Income in Millions -84 -137 -140 -150 -66
Y / Y Net Income Change - - - - -
Return On Equity -31.81 % -91.18 % -52.97 % -56.64 % -16.78 %

Back to FPRX Management Effectiveness >> FPRX's 5 Years Annual ROE >> Compare FPRX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FPRX's' Return on Equity at Yahoo Finance
FPRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FPRX's Competitors
Subscribers only: Roe for Five Prime Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for FPRX's Customers




Companies with similar Return On Equity at Dec 31 2020, within Healthcare Sector ROE

Date modified: 2026-06-22T14:32:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.